Stress-induced Norepinephrine Downregulates CCL2 in Macrophages to Suppress Tumor Growth in a Model of Malignant Melanoma.
Adrenergic beta-Antagonists
/ pharmacology
Animals
Cell Line, Tumor
/ transplantation
Chemokine CCL2
/ genetics
Down-Regulation
/ immunology
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Macrophages
/ immunology
Melanoma, Experimental
/ genetics
Mice
Mice, Transgenic
Nadolol
/ pharmacology
Norepinephrine
/ antagonists & inhibitors
Restraint, Physical
Skin Neoplasms
/ genetics
Stress, Psychological
/ immunology
Tumor Microenvironment
/ drug effects
Journal
Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
29
08
2019
revised:
06
04
2020
accepted:
03
06
2020
pubmed:
11
6
2020
medline:
3
11
2021
entrez:
11
6
2020
Statut:
ppublish
Résumé
Psychological stressors have been implicated in the progression of various tumor types. We investigated a role for stress in tumor immune cell chemotaxis in the B16F10 mouse model of malignant melanoma. We exposed female mice to 6-hour periods of restraint stress (RST) for 7 days, then implanted B16F10 malignant melanoma tumor cells and continued the RST paradigm for 14 additional days. We determined serum corticosterone and liver catecholamine concentrations in these mice. To evaluate the tumor microenvironment, we performed IHC and examined cytokine expression profiles using ELISA-based analysis of tumor homogenates. We found that tumors in mice subjected to RST grew significantly slower, had reduced tumor C-C motif ligand 2 (CCL2), and contained fewer F4/80-positive macrophages than tumors from unstressed mice. We observed a concomitant increase in norepinephrine among the RST mice. An
Identifiants
pubmed: 32518084
pii: 1940-6207.CAPR-19-0370
doi: 10.1158/1940-6207.CAPR-19-0370
pmc: PMC7607650
mid: NIHMS1602976
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Ccl2 protein, mouse
0
Chemokine CCL2
0
Nadolol
42200-33-9
Norepinephrine
X4W3ENH1CV
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
747-760Subventions
Organisme : NCI NIH HHS
ID : R01 CA194013
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA100243
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL067176
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA131552
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA131552
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
J Neuroimmunol. 1997 Mar;73(1-2):81-9
pubmed: 9058763
Cell. 2000 Oct 27;103(3):481-90
pubmed: 11081634
Cell. 2010 Jul 9;142(1):52-64
pubmed: 20603014
Oncoimmunology. 2017 Dec 21;7(3):e1405205
pubmed: 29399407
Onco Targets Ther. 2018 Aug 20;11:4913-4944
pubmed: 30174436
Immunol Allergy Clin North Am. 2009 May;29(2):285-93
pubmed: 19389582
Ann N Y Acad Sci. 1998 May 1;840:803-8
pubmed: 9629306
Drug Saf. 2018 Feb;41(2):161-169
pubmed: 28905299
Surgery. 2007 Aug;142(2):170-9
pubmed: 17689682
Br J Cancer. 2005 Feb 14;92(3):553-61
pubmed: 15668703
Stress. 2009 Mar;12(2):134-43
pubmed: 18609297
Cancer Cell. 2011 Apr 12;19(4):512-26
pubmed: 21481792
Melanoma Res. 2017 Jun;27(3):268-270
pubmed: 28346289
Int J Cancer. 2009 Sep 15;125(6):1276-84
pubmed: 19479998
Br J Dermatol. 2014 Apr;170(4):930-8
pubmed: 24593055
J Neuroimmunol. 2006 Feb;171(1-2):29-37
pubmed: 16253348
Cancer Res. 2007 Jun 1;67(11):5064-6
pubmed: 17545580
Brain Behav Immun. 2016 Oct;57:338-346
pubmed: 27485040
J Immunol. 2013 May 1;190(9):4861-7
pubmed: 23536638
Cancer Res. 2017 Oct 15;77(20):5639-5651
pubmed: 28819022
Front Immunol. 2018 Feb 06;9:164
pubmed: 29479349
J Immunol. 1996 Sep 1;157(5):1870-7
pubmed: 8757304
J Clin Invest. 2013 Mar;123(3):1371-81
pubmed: 23454771
Brain Behav Immun. 2010 Jan;24(1):127-37
pubmed: 19765644
Eur J Cancer. 1995;31A(2):157-62
pubmed: 7718319
Lancet. 1995 Nov 4;346(8984):1194-6
pubmed: 7475659
Oncotarget. 2015 Feb 28;6(6):4266-73
pubmed: 25738355
Genes Dev. 2011 Jun 15;25(12):1245-61
pubmed: 21646373
Physiol Behav. 2009 Sep 7;98(3):351-8
pubmed: 19560480
Blood. 2007 Jun 15;109(12):5276-85
pubmed: 17327411
Oncol Rep. 2005 Aug;14(2):425-31
pubmed: 16012726
J Neuroimmunol. 2007 May;186(1-2):45-53
pubmed: 17428549
Am J Gastroenterol. 2004 Sep;99(9):1667-74
pubmed: 15330899
Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):15126-15131
pubmed: 27956622
Immunology. 2000 Jul;100(3):359-63
pubmed: 10929058
Immunology. 2018 Nov;155(3):285-293
pubmed: 29963704
BMB Rep. 2015 May;48(5):295-300
pubmed: 25748171
Life Sci. 1995;56(9):661-6
pubmed: 7869847
Neurosci Biobehav Rev. 2009 Jul;33(7):1089-98
pubmed: 19463853
Int J Oncol. 2009 Apr;34(4):923-30
pubmed: 19287949
Cancer Res. 2006 Nov 1;66(21):10357-64
pubmed: 17079456
Cell Immunol. 2008 Mar-Apr;252(1-2):16-26
pubmed: 18279846
Brain Behav Immun. 1998 Mar;12(1):64-73
pubmed: 9570862
Br J Pharmacol. 2017 Jan;174(2):139-149
pubmed: 27792834
J Invest Dermatol. 2002 Jun;118(6):915-22
pubmed: 12060384
Neurochem Int. 2006 Jul;49(1):94-103
pubmed: 16515823
World J Surg. 2004 Mar;28(3):327-30
pubmed: 14961184
Am J Physiol. 1997 Dec;273(6):E1203-8
pubmed: 9435537
Biochem Biophys Res Commun. 2018 Jan 1;495(1):1108-1114
pubmed: 29175389
Int J Cancer. 2000 Jan 15;85(2):182-8
pubmed: 10629075